Sign in
Taking people in United StatesNo phase

Cephea Early Feasibility Study

Key facts

Who runs it
Abbott Medical Devices
Where
Ann Arbor, Atlanta, Charlotte, Chicago, Cleveland, Houston, Los Angeles, Minneapolis, Nashville, New York, Norfolk, Phoenix, Pittsburgh, Sacramento, Seattle, The Bronx, Thousand Oaks, and Wichita, United StatesSee the 20 sitesAlso in 1 other country, 2 sites
Trial code
Status
Recruiting
People taking part
90 people, planned
Started
28 Apr 2022
Expected to end
1 Mar 2031
Type of study
Interventional
Treatments tested
  • Cephea Mitral Valve System
Record updated
11 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm² and/or mean transmitral gradient ≥10 mmHg at normal heart rate) per American Society of Echocardiography criteria
  • LVEF ≥ 30%
  • In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery

Who cannot take part

  • Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function
  • Need for emergent or urgent surgery

Where in United States

Also in 1 other country, 2 sites

  • University of Michigan - Davis Medical CenterAnn Arbor, United StatesContact: Allison SchleyTaking people
  • Emory University HospitalAtlanta, United StatesContact: Elizabeth CharlesTaking people
  • Piedmont Heart InstituteAtlanta, United StatesContact: Danielle GriffithTaking people
  • Atrium Health - Carolinas Medical CenterCharlotte, United StatesContact: Montana BrightTaking people
  • Northwestern Memorial HospitalChicago, United StatesContact: Maggie McNamaraTaking people
  • The Cleveland Clinic FoundationCleveland, United StatesContact: Emily TylickiTaking people
  • Houston MethodistHouston, United StatesContact: Deena VictorTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Andjela KremenovicTaking people
  • Minneapolis Heart InstituteMinneapolis, United StatesContact: Jennifer NguyenTaking people
  • Ascension Saint ThomasNashville, United StatesContact: Kolie GasawayTaking people
  • Vanderbilt Heart & Vascular InstituteNashville, United StatesContact: Kathryn AdamsTaking people
  • New York Presbyterian/Columbia University Medical CenterNew York, United StatesContact: Kate DaltonTaking people
  • Sentara Norfolk General HospitalNorfolk, United StatesContact: Christine CalayoTaking people
  • Banner-University Medical Center PhoenixPhoenix, United StatesContact: Paul Sorajja, MD (principal investigator)Taking people
  • Allegheny General Hospital - ASRIPittsburgh, United StatesContact: Tracy SpirkTaking people
  • University of California, Davis Medical CenterSacramento, United StatesContact: Heather HoustonTaking people
  • Swedish Medical CenterSeattle, United StatesContact: Jennifer NagelTaking people
  • Montefiore Medical Center - Moses CampusThe Bronx, United StatesContact: Tammy Rodriguez GuzmanTaking people
  • Los Robles Regional Medical CenterThousand Oaks, United StatesContact: Mane ArabyanTaking people
  • Ascension Via Christi Hospitals WichitaWichita, United StatesContact: Lindsey SteeleTaking people

About the trial

What the trial wants to find out

The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.

The group in the trial

  • TreatmentTreatment being tested

    Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System

    Treatment: Cephea Mitral Valve System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 September 2026